Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00842023 · ClinicalTrials.gov registry record · Phase 4
Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy
A Phase 4 study, sponsored by Western University of Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
NCT00842023 is a Phase 4 study that has completed, run by Western University of Health Sciences. The registered enrollment target is 89 participants.
The verdict
NCT00842023, a Phase 4 study, has completed, sponsored by Western University of Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.
Interventions
- DRUG Nitroglycerin
- DRUG Nesiritide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00842023
The ClinicalTrials.gov registry entry for NCT00842023 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western University of Health Sciences, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nitroglycerin is the first listed.
NCT00842023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00842023 about?
NCT00842023 is a clinical study titled "Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy". The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.
What is the current status of trial NCT00842023?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2006-07. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00842023?
The interventions under investigation include: Nitroglycerin (DRUG), Nesiritide (DRUG).
Who is sponsoring clinical trial NCT00842023?
This trial is sponsored by Western University of Health Sciences, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.